GS-248

DRUG2 trials

Sponsors

Gesynta Pharma AB

Conditions

HealthySystemic Sclerosis

Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248

CompletedNCT04036227

Gesynta Pharma ABHealthy

Start: 2019-07-03End: 2019-12-20Updated: 2023-10-11

Phase 2

A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis

CompletedNCT04744207

Gesynta Pharma ABSystemic Sclerosis

Start: 2020-12-29End: 2022-06-15Updated: 2024-08-09